Correspondence 0001193125-23-148000 from BIOCEPT INC (BIOCQ) (CIK 0001044378)
BIOCEPT INC (BIOCQ) (CIK 0001044378)
Date: May 18, 2023 · CIK: 0001044378 · Accession: 0001193125-23-148000
AI Filing Summary & Sentiment
File numbers found in text: 333-271355
Letter
Biocept, Inc.
5810 Nancy Ridge Drive
San Diego, CA 92121
May 18, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jessica Ansart
Re: Biocept, Inc.
Registration Statement on Form S-1, as amended (File No. 333-271355)
Ladies and Gentlemen:
Biocept, Inc. (the “Company”) hereby withdraws its request, dated May 16, 2023, that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Time, on May 18, 2023. The Company intends to submit a revised acceleration request for the Registration Statement at a later date.
Please contact Charles J. Bair of Cooley LLP at (858) 550-6142 or Asa M. Henin of Cooley LLP at (858) 550-6104, counsel to the Company, if there are any questions regarding this matter.
Very truly yours,
Biocept, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Ladies and Gentlemen: Biocept, Inc. (the “Company”) hereby withdraws its request, dated May 16, 2023, that the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Time, on May 18, 2023. The Company intends to submit a revised acceleration request for the Registration Statement at a later date. Please contact Charles J. Bair of Cooley LLP at (858) 550-6142 or Asa M. Henin of Cooley LLP at (858) 550-6104, counsel to the Company, if there are any questions regarding this matter. Very truly yours, Biocept, Inc. /s/ Samuel D. Riccitelli By: Samuel D. Riccitelli Title: Interim President and Chief Executive Officer